Bionxt moves cladribine ODF to clinic

Executive Summary

• Bionxt Solutions Inc. reports a greater than 40% improvement in bioavailability for its proprietary cladribine oral thin film (ODF) formulation compared to conventional tablets, marking a key milestone toward human clinical studies.
• The company is advancing its lead program, BNT23001, for Multiple Sclerosis (MS) toward a first-in-human clinical study, leveraging the established safety profile of cladribine to focus on bioavailability and bioequivalence rather than large-scale safety trials.
• Bionxt is expanding its cladribine ODF strategy into Myasthenia Gravis (MG), a rare autoimmune neuromuscular disease, utilizing the same active ingredient and delivery platform to pursue an accelerated, capital-efficient development pathway.

Key Details

• Bioavailability Improvement: Recent study results demonstrate a >40% improvement in bioavailability for the cladribine oral thin film compared to conventional formulations.
• MS Program (BNT23001):
  • Development focus is shifting to human clinical evaluation, specifically demonstrating bioavailability and bioequivalence.
  • The company is collaborating with an experienced Clinical Research Organization (CRO) for study design, operational execution, and regulatory compliance.
  • Current activities include clinical planning, manufacturing readiness, and regulatory alignment.
• MG Expansion:
  • The strong bioavailability data enables the expansion of the cladribine ODF platform into Myasthenia Gravis (MG).
  • MG affects an estimated 1.4 million people worldwide; symptoms include fluctuating muscle weakness and difficulty swallowing, making the swallow-free ODF format particularly suitable.
  • The MG program repurposes the same cladribine drug and ODF technology as the MS program, allowing for accelerated development relative to a de novo drug.
• Market Context:
  • MS Market: Estimated at $32.8 billion (U.S.) in 2024 across 68 markets, projected to reach $41.2 billion by 2034.
  • Competitor Data: Merck KGaA’s Mavenclad (oral cladribine) reported 2024 net sales of >$1 billion (U.S.).
  • MG Market: Forecast to reach approximately $6.7 billion (U.S.) by 2032 across the seven major markets (7MM).
• Strategic Approach: The company emphasizes a capital-efficient, execution-driven pathway by leveraging an already approved active pharmaceutical ingredient (cladribine) and a differentiated delivery format to improve patient adherence and simplify administration.

Notable Quotes

• "Recent study results demonstrating a greater than 40-per-cent improvement in bioavailability compared with conventional formulations represent a key development milestone and support the company's transition toward human clinical evaluation."
• "Development focus now moves toward human clinical study, which is expected to be more streamlined and efficient because cladribine is an already approved active pharmaceutical ingredient, allowing the company's clinical work to concentrate on demonstrating bioavailability and bioequivalence rather than repeating large-scale safety and efficacy trials."
• "Bionxt believes its sublingual, needle-free oral thin film delivery format may be particularly well suited for MG patients by simplifying administration and reducing reliance on swallowing intact tablets."